This educational program consists of three presentations on CETP inhibition.

This course consists of the following:

• Lessons from the biology of CETP inhibition - Prof. John Kastelein, MD, PhD - Amsterdam, The Netherlands
• What have we learned from previous CETP inhibitor outcome trials? - Prof. Stephen Nicholls, MD - Melbourne, Australia
• LDL-c lowering with CETP inhibitor in patients on high intensity statins - Prof. Kausik Ray, MD - London, UK

How to obtain your CME certificate

• Watch the three lectures and answer the pre- and post-test questions
• Fill in the evaluation questions
• Download CME Certificate (if your score >70%)

After watching these three videos, the learner should be able to:

• Explain how CETP inhibition can reduce the risk of CHD
• Recall the reasons why earlier generation CETP inhibitors were unsuccessful in reducing CHD risk
• Reproduce the design (and outcomes) of recently completed and ongoing studies with the CETP inhibitor anacetrapib and obicetrapib

Expert faculty

• Prof. John Kastelein, MD, PhD - Amsterdam, The Netherlands
• Prof. Stephen Nicholls, MD - Melbourne, Australia
• Prof. Kausik Ray, MD - London, UK

Target audience

This educational activity is designed for all healthcare professionals with an interest in management of patients with hypercholesterolemia.

CME accreditation

This online course is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credit.

Through an agreement between EBAC and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.

Funding

Funding for this educational program was provided by an unrestricted educational grant from New Amsterdam Pharma.

Questions

For questions regarding this activity, please contact us at info@pace-cme.org.